NCT06122181招募中1 期
A Randomized, Double-blind, Placebo-controlled Phase Ib Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HS-10384 in Chinese Postmenopausal Women
Hansoh BioMedical R&D Company1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2023年11月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Number of participants with abnormalities of vital signs
研究概览
简要总结
A randomized, double-blind, placebo-controlled phase Ib clinical study to evaluate the safety, tolerability and pharmacokinetics characteristics of HS-10384 in Chinese postmenopausal women.
详细描述
Phase Ib is consisted with 3~4 multiple ascending doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 40 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Subjects should fully understand the content, process and possible adverse reactions of the study, and voluntarily sign the informed consent form;
- •Age between 40 and 65 years old (including the critical value);
- •The body mass index (BMI=body weight [kg]/height2 [m2]) at screening is 19~28 kg/m2 (including the critical value of 19), and the weight is ≥ 40 kg;
- •Subjects are postmenopausal women at screening as qualified by any of the following criteria: spontaneous amenorrhea ≥ 12 months, or spontaneous amenorrhea ≥ 6 months and FSH>40 IU/L (without other obvious pathological or physiological reasonsbefore screening), or documented surgical sterilization (such as hysterectomy, bilateral salpingectomy or bilateral oophorectomy, etc.);
- •From 48 hours before taking drug to the end of the study, subjects should avoid taking tobacco products, alcohol and other foods or drinks that might affect drug metabolism (such as coffee, tea, cola or other caffeinated drinks);
- •The blood pregnancy test of female subjects at baseline period is negative.
排除标准
- •Participants with disease history of uterine bleeding, uterine ovarian tumor, pituitary tumor, or other diseases evaluated by the principal investigator as not suitable for this study;
- •Have a history of migraine within 3 months before screening;
- •Participants with clinically significant diseases (such as neuropsychiatric system, cardiovascular system, urinary system, digestive system, respiratory system, skeletal muscle system, endocrine and metabolic system, blood system, skin disease, immune system, tumor, etc.) were evaluated by the researcher as not suitable for this study;
- •Within 2 weeks before screening, participants have suffered from VMS that inducing the interrupt of daily activities;
- •Within 30 days before taking drug, participants have taken hormonal treatment or other therapy due to VMS;
- •Within 4 weeks or 5 half-lives (whichever is longer) before screening, and during the whole study period, it is expected to take any medicine and health care products, including prescription drugs, immunomodulator or Chinese herbal medicine, etc.;
- •Within 3 months before screening, participants have taken hormonal contraceptive;
- •Participants have participated in any clinical study or taken study drugs within 3 months before screening;
研究组 & 干预措施
HS-10384
Experimental
Multiple ascending doses of HS-10384 orally
干预措施: HS-10384 tablets (Drug)
Placebo
Placebo Comparator
Multiple ascending doses of HS-10384 placebo orally
干预措施: HS-10384-matched placebo tablets (Drug)
结局指标
主要结局
Number of participants with abnormalities of vital signs
时间窗: Day 1 to Day 21
Number of participants with clinical laboratory abnormalities
时间窗: Day 1 to Day 21
Clinical laboratory tests include blood routine, blood biochemistry, coagulation function, urine routine, thyroid function,etc.
The incidence and severity of adverse events (AE), serious adverse events (SAE) and adverse events leading to withdrawal from the trial and the correlation with the investigational drug;
时间窗: Day 1 to Day 21
Number of participants with abnormalities of physical examination
时间窗: Day 1 to Day 21
次要结局
- Cmax(Day 1 to Day 13)
- Tss,max(Day 14 to Day 21)
- Css,max(Day 14 to Day 21)
- AUCss(Day 14 to Day 21)
- Tmax(Day 1 to Day 13)
- Css,min(Day 14 to Day 21)
- RAC(Day 14 to Day 21)
- AUC0-24(Day 1 to Day 13)
- Luteinizing hormone changes from baseline(Day 1 to Day 21)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
A Study to Evaluate the Safety and Effect of STC314 Injection Continuous Infusion in Subjects With Acute Respiratory Distress SyndromeAcute Respiratory Distress SyndromeNCT05000671Grand Medical Pty Ltd.16
撤回
1 期
Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 PatientsSARS CoV 2 InfectionNCT05596045Ascletis Pharmaceuticals Co., Ltd.32
尚未招募
1 期
A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.Atopic DermatitisNCT06175143Genrix (Shanghai) Biopharmaceutical Co., Ltd.40
Unknown
1 期
A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.Esophageal CancerNCT04460066Lee's Pharmaceutical Limited70
已完成
1 期
A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044Health VolunteerNCT05539651Suzhou Ribo Life Science Co. Ltd.72